{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,25]],"date-time":"2026-10-25T12:37:16Z","timestamp":1792931836633,"version":"4.5.0"},"reference-count":39,"publisher":"MDPI AG","issue":"7","license":[{"start":{"date-parts":[[2025,3,29]],"date-time":"2025-03-29T00:00:00Z","timestamp":1743206400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Background\/Objectives: Acute myeloid leukemia (AML) is a biologically heterogeneous malignancy with a variable prognosis. Despite many patients achieving complete remission, relapse remains common, underscoring the need for effective prognostic markers. Measurable residual disease (MRD) has emerged as a critical prognostic indicator, associated with higher relapse risk and shorter survival. This study reports on our initial experience of MRD detection by flow cytometry in 385 bone marrow samples from 126 AML patients. Methods: The flow cytometry MRD assay, validated according to stringent consensus recommendations, consists of a 3-tube, 10-color panel incorporating a broad spectrum of lineage differentiation markers. Analytical specificity, sensitivity, precision, and reproducibility were evaluated, demonstrating the assay\u2019s robustness. Results: The results reveal distinct immunophenotypic aberrancies in all AML cases, with consistent identification of aberrant immunophenotypes in follow-up specimens. AML MRD was detected in 32 out of 126 patients (25%) and in 77 out of 385 analyses (20%), with a median aberrant blast percentage of 1.87% (range, 0.01\u201312). A change in immunophenotype was documented in 21% of the MRD-positive cases. MRD positivity detected in the first sample studied was associated with reduced overall survival (HR: 5.153; p &lt; 0.0001). Conclusions: Our findings support the integration of flow cytometric MRD analysis into routine clinical practice to enhance risk stratification and treatment planning for AML patients, as currently recommended by professional guidelines.<\/jats:p>","DOI":"10.3390\/cancers17071155","type":"journal-article","created":{"date-parts":[[2025,3,31]],"date-time":"2025-03-31T01:59:36Z","timestamp":1743386376000},"page":"1155","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Measurable Residual Disease Analysis by Flow Cytometry: Assay Validation and Characterization of 385 Consecutive Cases of Acute Myeloid Leukemia"],"prefix":"10.3390","volume":"17","author":[{"given":"Husam A.","family":"Jum\u2019ah","sequence":"first","affiliation":[{"name":"Division of Hematopathology, Department of Pathology and Laboratory Medicine, Mayo Clinic, Rochester, MN 55905, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory E.","family":"Otteson","sequence":"additional","affiliation":[{"name":"Division of Hematopathology, Department of Pathology and Laboratory Medicine, Mayo Clinic, Rochester, MN 55905, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael M.","family":"Timm","sequence":"additional","affiliation":[{"name":"Division of Hematopathology, Department of Pathology and Laboratory Medicine, Mayo Clinic, Rochester, MN 55905, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-5658-936X","authenticated-orcid":false,"given":"Matthew J.","family":"Weybright","sequence":"additional","affiliation":[{"name":"Division of Hematopathology, Department of Pathology and Laboratory Medicine, Mayo Clinic, Rochester, MN 55905, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5741-4293","authenticated-orcid":false,"given":"Min","family":"Shi","sequence":"additional","affiliation":[{"name":"Division of Hematopathology, Department of Pathology and Laboratory Medicine, Mayo Clinic, Rochester, MN 55905, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4909-6157","authenticated-orcid":false,"given":"Pedro","family":"Horna","sequence":"additional","affiliation":[{"name":"Division of Hematopathology, Department of Pathology and Laboratory Medicine, Mayo Clinic, Rochester, MN 55905, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dragan","family":"Jevremovic","sequence":"additional","affiliation":[{"name":"Division of Hematopathology, Department of Pathology and Laboratory Medicine, Mayo Clinic, Rochester, MN 55905, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaaren K.","family":"Reichard","sequence":"additional","affiliation":[{"name":"Division of Hematopathology, Department of Pathology and Laboratory Medicine, Mayo Clinic, Rochester, MN 55905, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5783-4485","authenticated-orcid":false,"given":"Horatiu","family":"Olteanu","sequence":"additional","affiliation":[{"name":"Division of Hematopathology, Department of Pathology and Laboratory Medicine, Mayo Clinic, Rochester, MN 55905, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,3,29]]},"reference":[{"key":"ref_1","unstructured":"WHO Classification of Tumours Editorial Board (2024). Acute myeloid leukaemia. WHO Classification of Tumours (5th Edition) Haematolymphoid Tumours Part A, International Agency for Research on Cancer."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1182\/blood.2022016867","article-title":"Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN","volume":"140","author":"Wei","year":"2022","journal-title":"Blood"},{"key":"ref_3","unstructured":"National Comprehenisve Cancer Network (2025, January 10). Acute Myeloid Leukemia (Version 1.2025). Available online: https:\/\/www.nccn.org\/login?ReturnURL=https:\/\/www.nccn.org\/professionals\/physician_gls\/PDF\/aml.pdf."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1016\/S0140-6736(18)31041-9","article-title":"Acute myeloid leukaemia","volume":"392","author":"Short","year":"2018","journal-title":"Lancet"},{"key":"ref_5","first-page":"2813","article-title":"How I treat AML incorporating the updated classifications and guidelines","volume":"141","author":"Hourigan","year":"2023","journal-title":"Blood"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1890","DOI":"10.1001\/jamaoncol.2020.4600","article-title":"Association of Measurable Residual Disease With Survival Outcomes in Patients With Acute Myeloid Leukemia: A Systematic Review and Meta-analysis","volume":"6","author":"Short","year":"2020","journal-title":"JAMA Oncol."},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Bernasconi, P., and Borsani, O. (2021). Eradication of Measurable Residual Disease in AML: A Challenging Clinical Goal. Cancers, 13.","DOI":"10.3390\/cancers13133170"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1667","DOI":"10.1038\/s41375-024-02300-z","article-title":"Pre-emptive detection and evolution of relapse in acute myeloid leukemia by flow cytometric measurable residual disease surveillance","volume":"38","author":"McCarthy","year":"2024","journal-title":"Leukemia"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"865","DOI":"10.3324\/haematol.2016.159343","article-title":"Minimal residual disease prior to allogeneic hematopoietic cell transplantation in acute myeloid leukemia: A meta-analysis","volume":"102","author":"Buckley","year":"2017","journal-title":"Haematologica"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1016\/j.path.2019.03.009","article-title":"Optimal Measurable Residual Disease Testing for Acute Myeloid Leukemia","volume":"12","author":"Xiao","year":"2019","journal-title":"Surg. Pathol. Clin."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1182\/blood.2020006219","article-title":"Acute myeloid leukemia measurable residual disease detection by flow cytometry in peripheral blood vs bone marrow","volume":"137","author":"Godwin","year":"2021","journal-title":"Blood"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1111\/bjh.17347","article-title":"Flow cytometric immunophenotypic alterations of persistent clonal haematopoiesis in remission bone marrows of patients with NPM1-mutated acute myeloid leukaemia","volume":"192","author":"Loghavi","year":"2021","journal-title":"Br. J. Haematol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1038\/s41375-018-0326-3","article-title":"CD34+CD38\u2212 leukemic stem cell frequency to predict outcome in acute myeloid leukemia","volume":"33","author":"Zeijlemaker","year":"2019","journal-title":"Leukemia"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1111\/bjh.16594","article-title":"Applicability and reproducibility of acute myeloid leukaemia stem cell assessment in a multi-centre setting","volume":"190","author":"Hanekamp","year":"2020","journal-title":"Br. J. Haematol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1186\/s13045-021-01148-5","article-title":"Prognostic and therapeutic implications of measurable residual disease in acute myeloid leukemia","volume":"14","author":"Aitken","year":"2021","journal-title":"J. Hematol. Oncol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1200\/JCO.21.01546","article-title":"Measurable Residual Disease Response and Prognosis in Treatment-Na\u00efve Acute Myeloid Leukemia With Venetoclax and Azacitidine","volume":"40","author":"Pratz","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"2145","DOI":"10.1182\/blood.2021013404","article-title":"Oral azacitidine prolongs survival of patients with AML in remission independently of measurable residual disease status","volume":"139","author":"Roboz","year":"2022","journal-title":"Blood"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.3324\/haematol.2018.208454","article-title":"How close are we to incorporating measurable residual disease into clinical practice for acute myeloid leukemia?","volume":"104","author":"Short","year":"2019","journal-title":"Haematologica"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41375-024-02458-6","article-title":"Pre-emptive therapeutic decisions based on measurable residual disease status in acute myeloid leukemia: Ready for prime time?","volume":"39","author":"Perissinotti","year":"2025","journal-title":"Leukemia"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.1038\/s41375-020-01100-5","article-title":"Value of flow cytometry for MRD-based relapse prediction in B-cell precursor ALL in a multicenter setting","volume":"35","author":"Modvig","year":"2021","journal-title":"Leukemia"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1182\/blood-2017-09-801498","article-title":"Minimal\/measurable residual disease in AML: A consensus document from the European LeukemiaNet MRD Working Party","volume":"131","author":"Schuurhuis","year":"2018","journal-title":"Blood"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"e676","DOI":"10.1097\/HS9.0000000000000676","article-title":"Technical Aspects of Flow Cytometry-based Measurable Residual Disease Quantification in Acute Myeloid Leukemia: Experience of the European LeukemiaNet MRD Working Party","volume":"6","author":"Tettero","year":"2022","journal-title":"Hemasphere"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"2753","DOI":"10.1182\/blood.2021013626","article-title":"2021 Update on MRD in acute myeloid leukemia: A consensus document from the European LeukemiaNet MRD Working Party","volume":"138","author":"Heuser","year":"2021","journal-title":"Blood"},{"key":"ref_24","unstructured":"Clinical and Laboratory Standards Institute (CLSI) (2021). Validation for Assays Performed by Flow Cytometry, CLSI."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"2399","DOI":"10.1002\/ajh.27484","article-title":"FDA IDE validation of multiple myeloma MRD test by flow cytometry","volume":"99","author":"Jevremovic","year":"2024","journal-title":"Am. J. Hematol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1093\/ajcp\/aqac083","article-title":"Abnormal CD13\/HLA-DR Expression Pattern on Myeloblasts Predicts Development of Myeloid Neoplasia in Patients With Clonal Cytopenia of Undetermined Significance","volume":"158","author":"Jevremovic","year":"2022","journal-title":"Am. J. Clin. Pathol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1111\/j.1365-2141.2010.08307.x","article-title":"Immunophenotypic stability of T-cell large granular lymphocytic leukaemia by flow cytometry","volume":"151","author":"Spears","year":"2010","journal-title":"Br. J. Haematol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1309\/AJCP7QHH5XASTJPL","article-title":"Immunophenotypic stability of S\u00e9zary cells by flow cytometry: Usefulness of flow cytometry in assessing response to and guiding alemtuzumab therapy","volume":"137","author":"Vaughan","year":"2012","journal-title":"Am. J. Clin. Pathol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1309\/AJCP8TF3WUIWLZHU","article-title":"Immunophenotypic stability of CD200 expression in plasma cell myeloma","volume":"137","author":"Olteanu","year":"2012","journal-title":"Am. J. Clin. Pathol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1309\/AJCPFNF5MN1GDWKU","article-title":"The specificity of immunophenotypic alterations in blasts in nonacute myeloid disorders","volume":"134","author":"Harrington","year":"2010","journal-title":"Am. J. Clin. Pathol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1309\/AJCP8G5RMTWUEMUU","article-title":"Characterization of immunophenotypic aberrancies in 200 cases of B acute lymphoblastic leukemia","volume":"132","author":"Seegmiller","year":"2009","journal-title":"Am. J. Clin. Pathol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1309\/AJCP73QSLLYDEGXK","article-title":"Loss of blast heterogeneity in myelodysplastic syndrome and other chronic myeloid neoplasms","volume":"142","author":"Jevremovic","year":"2014","journal-title":"Am. J. Clin. Pathol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1182\/blood-2013-06-506725","article-title":"Significance of minimal residual disease before myeloablative allogeneic hematopoietic cell transplantation for AML in first and second complete remission","volume":"122","author":"Walter","year":"2013","journal-title":"Blood"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1002\/cyto.b.22144","article-title":"Analytical assay validation for acute myeloid leukemia measurable residual disease assessment by multiparametric flow cytometry","volume":"104","author":"Tettero","year":"2023","journal-title":"Cytom. B Clin. Cytom."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"2823","DOI":"10.3324\/haematol.2021.279777","article-title":"Clinical relevance of an objective flow cytometry approach based on limit of detection and limit of quantification for measurable residual disease assessment in acute myeloid leukemia. A post-hoc analysis of the GIMEMA AML1310 trial","volume":"107","author":"Buccisano","year":"2022","journal-title":"Haematologica"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"2266","DOI":"10.1038\/s41375-024-02378-5","article-title":"Optimal prognostic threshold for measurable residual disease positivity by multiparameter flow cytometry in acute myeloid leukemia (AML)","volume":"38","author":"Othus","year":"2024","journal-title":"Leukemia"},{"key":"ref_37","first-page":"60","article-title":"Effect of age and treatment on predictive value of measurable residual disease: Implications for clinical management of adult patients with acute myeloid leukemia","volume":"109","author":"Mannelli","year":"2024","journal-title":"Haematologica"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1002\/cyto.b.22168","article-title":"MAGIC-DR: An interpretable machine-learning guided approach for acute myeloid leukemia measurable residual disease analysis","volume":"106","author":"Shopsowitz","year":"2024","journal-title":"Cytom. B Clin. Cytom."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"4339","DOI":"10.1182\/blood-2023-190275","article-title":"Machine Learning Enhancement of Flow Cytometry Data Accelerates the Identification of Minimal Residual Acute Myeloid Leukemia","volume":"14","author":"Seheult","year":"2023","journal-title":"Blood"}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/17\/7\/1155\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T17:05:26Z","timestamp":1760029526000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/17\/7\/1155"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,29]]},"references-count":39,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2025,4]]}},"alternative-id":["cancers17071155"],"URL":"https:\/\/doi.org\/10.3390\/cancers17071155","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,29]]}}}